In this issue:
Breast cancer inequities between Pasifika and NZ European women
Intense dose-dense chemotherapy benefits high-risk breast cancer
Outcomes of TNBC survivors
Cost-effectiveness of monthly denosumab vs 3-monthly zoledronic acid
Ultra-processed food intake and cancer risk
Osimertinib in EGFR-mutated advanced NSCLC
Nivolumab: durable responses in previously-treated NSCLC
Bevacizumab + chemotherapy in elderly mCRC patients
New-onset CV morbidity in older CRC patients
No benefits for bevacizumab maintenance in mCRC
Liquid biopsy RAS testing in mCRC
Please login below to download this issue (PDF)